Please provide your email address to receive an email when new articles are posted on . Two different doses of CC-90001 vs. placebo slowed decline of percentage of predicted FVC at week 24.
Please provide your email address to receive an email when new articles are posted on . Adverse events reported with ENV-101 have been seen with other hedgehog inhibitors. Another trial is already ...
In March 2025, The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by Academician Nan-shan Zhong and Professor Wei-jie Guan from ...
ACE inhibitors may reduce all-cause mortality in IPF patients, suggesting potential repurposing for this progressive disease. The study used electronic health records from 3579 IPF patients, matched ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications ...
Sanofi’s TSLP and IL-13 inhibitor has aced a pair of mid-stage studies for respiratory diseases, but missed on a phase 2 eczema trial. The asset, called lunsekimig, hit the primary endpoint of ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results